Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) Return on Capital Employed (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Return on Capital Employed for 6 consecutive years, with 0.49% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 5.0% to 0.49% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.49%, a 5.0% decrease, with the full-year FY2025 number at 0.42%, up 4.0% from a year prior.
  • Return on Capital Employed was 0.49% for Q4 2025 at Relay Therapeutics, roughly flat from 0.49% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.09% in Q1 2021 to a low of 0.49% in Q3 2025.
  • A 5-year average of 0.39% and a median of 0.42% in 2022 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: crashed -37bps in 2021, then grew 17bps in 2022.
  • Relay Therapeutics' Return on Capital Employed stood at 0.45% in 2021, then skyrocketed by 37bps to 0.28% in 2022, then plummeted by -58bps to 0.44% in 2023, then rose by 1bps to 0.44% in 2024, then fell by -11bps to 0.49% in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Return on Capital Employed are 0.49% (Q4 2025), 0.49% (Q3 2025), and 0.47% (Q2 2025).